Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer

被引：34

作者：

Solomon, Benjamin J. ^{[1
]}

Zhou, Cai Cun ^{[2
]}

Drilon, Alexander ^{[3
]}

Park, Keunchil ^{[4
]}

Wolf, Jurgen ^{[5
]}

Elamin, Yasir ^{[6
]}

Davis, Hannah M. ^{[7
]}

Soldatenkova, Victoria ^{[7
]}

Sashegyi, Andreas ^{[7
]}

Lin, Aimee Bence ^{[7
]}

Lin, Boris K. ^{[7
]}

Loong, Herbert H. ^{[8
]}

Novello, Silvia ^{[9
]}

Arriola, Edurne ^{[10
]}

Perol, Maurice ^{[11
]}

Goto, Koichi ^{[12
]}

Santini, Fernando C. ^{[13
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Shanghai Pulm Hosp, Shanghai, Peoples R China

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[4] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Eli Lilly & Co, Indianapolis, IN 46225 USA

[8] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[9] Univ Turin, Dept Oncol, AOU San Luigi Orbassano, Turin, Italy

[10] Hosp del Mar, Barcelona, Spain

[11] Leon Berard Canc Ctr Lyon, Lyon, France

[12] Natl Canc Ctr Hosp East, Chiba, Japan

[13] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 07期

关键词：

non-small-cell lung cancer; Phase III trial; RET fusion-positive; RET kinase inhibitor; RET rearrangement; selpercatinib; targeted therapy; ALK; REARRANGEMENTS; EFFICACY; FUSIONS; IPILIMUMAB; MUTATIONS; BLOCKADE; NSCLC; EGFR; BRAF;

D O I：

10.2217/fon-2020-0935

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival.

引用

页码：763 / 773

页数：11

共 50 条

[31] Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer [J].

Wang, Haowei ;

Cheng, Lei ;

Chen, Jian ;

Chen, Peixin ;

Tang, Zhuoran ;

Wang, Qianyi ;

Ma, Ying ;

Zhao, Chao ;

Li, Xuefei ;

Jiang, Tao ;

Zhou, Fei ;

Chen, Xiaoxia ;

Zhou, Caicun .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)

[32] Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer [J].

Hochmair, Maximilian ;

Kiiskinen, Urpo ;

D'yachkova, Yulia ;

Puri, Tarun ;

Wang, Xuwen ;

Wolowacz, Sorrel ;

Vickers, Adrian ;

Nadal, Ernest .

FUTURE ONCOLOGY, 2025, 21 (15) :1867-1878

[33] An Indirect Comparison Between Nivolumab plus Ipilimumab plus Two Cycles of Chemotherapy vs. Pembrolizumab plus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer [J].

Jiang, Panpan ;

Mao, Ziyang ;

Wang, Qinyang ;

Jia, Xiaohui ;

Geng, Luying ;

Xu, Hong ;

Jiang, Lili ;

Yang, Chengcheng ;

Jiao, Min ;

Guo, Hui .

FRONTIERS IN ONCOLOGY, 2021, 11

[34] Rare mutations in non-small-cell lung cancer [J].

D'Arcangelo, Manolo ;

D'Incecco, Armida ;

Cappuzzo, Federico .

FUTURE ONCOLOGY, 2013, 9 (05) :699-711

[35] Molecular targeted therapy of patients with non-small-cell lung cancer [J].

Stencel, Katarzyna ;

Swiniuch, Daria ;

Ramlau, Rodryg .

ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (06) :289-296

[36] RET-rearranged non-small-cell lung cancer and therapeutic implications [J].

Loh, Zoe ;

Mitchell, Paul ;

John, Thomas ;

Arulananda, Surein .

INTERNAL MEDICINE JOURNAL, 2019, 49 (12) :1541-1545

[37] TROPION-Lung07: Phase III study of Dato-DXd plus pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer [J].

Okamoto, Isamu ;

Kuyama, Shoichi ;

Girard, Nicolas ;

Lu, Shun ;

Franke, Fabio ;

Li, Ziming ;

Danchaivijitr, Pongwut ;

Han, Ji-Youn ;

Sun, Jong-Mu ;

Sugawara, Shunichi ;

Pan, Edward ;

Ren, Natalie ;

Chen, Aiying ;

Rajagopalan, Rachana ;

Lisberg, Aaron E. .

FUTURE ONCOLOGY, 2024, 20 (37) :2927-2936

[38] Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial [J].

Lu, S. ;

Cheng, Y. ;

Huang, D. ;

Sun, Y. ;

Wu, L. ;

Zhou, C. ;

Zhou, J. ;

Guo, Y. ;

Chen, L. ;

Shao, J. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) :S888-S889

[39] RET fusion in advanced non-small-cell lung cancer and response to cabozantinib A case report [J].

Wang, Yucong ;

Xu, Yinghui ;

Wang, Xu ;

Sun, Chao ;

Guo, Ye ;

Shao, Guoguang ;

Yang, Zhiguang ;

Qiu, Shi ;

Ma, Kewei .

MEDICINE, 2019, 98 (03)

[40] RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer [J].

Wang, Rui ;

Hu, Haichuan ;

Pan, Yunjian ;

Li, Yuan ;

Ye, Ting ;

Li, Chenguang ;

Luo, Xiaoyang ;

Wang, Lei ;

Li, Hang ;

Zhang, Yang ;

Li, Fei ;

Lu, Yongming ;

Lu, Qiong ;

Xu, Jie ;

Garfield, David ;

Shen, Lei ;

Ji, Hongbin ;

Pao, William ;

Sun, Yihua ;

Chen, Haiquan .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) :4352-4359

← 1 2 3 4 5 →